High Serum Levels of the Interleukin-33 Receptor Soluble ST2 as a Negative Prognostic Factor in Hepatocellular Carcinoma.

IF 4.5 2区医学 Q1 ONCOLOGY

Translational Oncology Pub Date : 2013-04-01 DOI:10.1016/S0168-8278(13)60632-7

D. Bergis, Valentin Kassis, Annika Ranglack, V. Koeberle, A. Piiper, B. Kronenberger, S. Zeuzem, O. Waidmann, H. Radeke

引用次数: 91

查看原文本刊更多论文

高水平血清白细胞介素-33受体可溶性ST2作为肝细胞癌的一个阴性预后因素

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

7.20

自引率

2.00%

发文量

314

审稿时长

6-12 weeks

期刊介绍： Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.